Document:

Form of October 2012 Warrant

 Exhibit 10.53 
 STOCK PURCHASE WARRANT 
 To Purchase Common Stock of 

CANCER GENETICS, INC. 

 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE ACT) NOR UNDER ANY STATE
SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNTIL (1) A REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAW HAS BECOME EFFECTIVE WITH RESPECT THERETO, OR (2) RECEIPT BY THE
COMPANY OF AN OPINION OF COUNSEL TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW IS NOT REQUIRED IN CONNECTION WITH THE PROPOSED TRANSFER. 

Void after 5:00 p.m. Eastern Standard Time, on October 17, 2022. 

Warrant to Purchase
                 Shares of Common Stock. 

WARRANT TO PURCHASE COMMON STOCK 
 OF 
 CANCER GENETICS, INC. 
 Warrant No. 
 This is to Certify That, FOR VALUE RECEIVED,
                 (Holder) is entitled to purchase, subject to the provisions of this Warrant, from CANCER GENETICS, INC., a Delaware corporation (Company),
                 fully paid, validly issued and nonassessable shares of common stock, par value $0.0001 per share, of the Company (Common Stock) at a price of
Eight Dollars and fifty cents ($8.50) per share at any time or from time to time during the period from the date hereof to 5:00 p.m. Eastern Standard Time, on October 17, 2022. The number of shares of Common Stock to be received upon the
exercise of this Warrant and the price to be paid for each share of Common Stock may be adjusted from time to time as hereinafter set forth. The exercise price and the number of shares issuable upon exercise of this Warrant will be proportionately
adjusted for stock splits, stock dividends, recapitalizations and similar transactions. The shares of Common Stock deliverable upon such exercise, and as adjusted from time to time, are hereinafter sometimes referred to as Warrant Shares and the
exercise price of a share of Common Stock in effect at any time and as adjusted from time to time is hereinafter sometimes referred to as the Exercise Price. 
  

	 	(a)	EXERCISE OF WARRANT. 

  

	 	(1)	 This Warrant may be exercised in whole or in part at any time or from time to time on or after the date hereof and until 5:00 p.m. Eastern Standard
Time on October 17, 2022; provided, however, that if either such day is a day on which banking institutions in the State of New York are authorized by law to close, then on the next succeeding day which shall

	 	
not be such a day. This Warrant may be exercised by presentation and surrender hereof to the Company at its principal office, or at the office of its stock transfer agent if any, with the
Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Warrant Shares specified in such form. As soon as practicable after each such exercise of this Warrant, but not later than fourteen
(14) days from the date of such exercise, the Company shall issue and deliver to the Holder a certificate or certificates for the Warrant Shares issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant
should be exercised in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the rights of the Holder thereof to purchase the balance of the Warrant Shares purchasable thereunder.
Upon receipt by the Company of this Warrant at its office, or by the stock transfer agent of the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder of record of the shares of Common Stock issuable upon
such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such shares of Common Stock shall not then be physically delivered to the Holder. 

 

	 	(2)	In lieu of delivering the Exercise Price in cash or check the Holder may elect to receive shares of Common Stock equal to the value of the Warrant or portion thereof
being exercised (Net Issue Exercise). If the Holder wishes to elect the Net Issue Exercise, the Holder shall notify the Company of its election in writing at the time it delivers to the Company the Purchase Form. In the event the Holder shall elect
Net Issue Exercise, the Holder shall receive the number of shares of Common Stock equal to the product of (a) the number of shares of Common Stock purchasable under the Warrant, or portion thereof being exercised, and (b) the current
market value, as defined in paragraph (c), of one share of Common Stock minus the Exercise Price, divided by (c) the current market value, as defined below, of one share of Common Stock. 

 

	 	(3)	In the event that this Warrant (or any portion of this Warrant) is exercised prior to the consummation of an initial public offering of its securities registered with
the Securities and Exchange Commission (an IPO), the Holder and the Company shall enter into a Joinder Agreement, substantially in the form annexed hereto, pursuant to which the Holder shall become a party to the Amended and Restated
Stockholders’ Agreement, dated as of April 13, 2010, by and among the Company and the individuals or entities listed on Schedule I, Schedule II and Schedule III thereto, as amended from time to time. 

 

	 	(4)	 Notwithstanding anything herein to the contrary and if Holder has not otherwise exercised this Warrant in total, on the expiration date of this

  
 -2-

	 	
Warrant, the Warrant shall be automatically exercised via Net Issue Exercise pursuant to Section (a)(2) above. 

 

	 	(b)	RESERVATION OF SHARES. The Company shall at all times reserve for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common
Stock as shall be required for issuance and delivery upon exercise of this Warrant. 

  

	 	(c)	FRACTIONAL SHARES. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction
of a share of Common Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of a share of Common Stock, determined as follows:

  

	 	(1)	If the Common Stock is listed on a national securities exchange or admitted to unlisted trading privileges on such exchange or listed for trading on the NASDAQ system,
the current market value shall be the last reported sale price of the Common Stock on such exchange or system on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day, the average closing bid and
asked prices for such day on such exchange or system; or 

  

	 	(2)	If the Common Stock is not so listed or admitted to unlisted trading privileges, the current market value shall be the mean of the last reported bid and asked prices
reported by the National Quotation Bureau, Inc. on the last business day prior to the date of the exercise of this Warrant; or 

  

	 	(3)	If the Common Stock is not so listed or admitted to unlisted trading privileges and bid and asked prices are not so reported, the current market value shall be an
amount, not less than the book value thereof as at the end of the most recent fiscal year of the Company ending prior to the date of the exercise of the Warrant, determined in such reasonable manner as may be prescribed by the Board of Directors of
the Company. 

  

	 	(d)	EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender
hereof to the Company or at the office of its stock transfer agent, if any, for other warrants of different denominations entitling the holder thereof to purchase in the aggregate the same number of shares of Common Stock purchasable hereunder. Upon
surrender of this Warrant to the Company at its principal office or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without
charge, execute and deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled. This Warrant may be divided or combined with other warrants which carry the same rights upon
presentation 

  
 -3-

	 	
hereof at the principal office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are
to be issued and signed by the Holder hereof. The term Warrant as used herein includes any Warrants into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant, and (in the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and deliver a new Warrant of like
tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at any time enforceable by
anyone. 

  

	 	(e)	RIGHTS OF THE HOLDER. The Holder shall not, by virtue hereof, be entitled to any rights of a shareholder in the Company, either at law or equity, and the rights
of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein. 

  

	 	(f)	ANTI-DILUTION PROVISIONS AND PRICE ADJUSTMENT. The Exercise Price in effect at any time and the number and kind of securities purchasable upon the exercise of
this Warrant shall be subject to adjustment from time to time upon the happening of certain events as follows: 

  

	 	(1)	In case the Company shall (i) declare a dividend or make a distribution on its outstanding shares of Common Stock in shares of Common Stock, (ii) subdivide or
reclassify its outstanding shares of Common Stock into a greater number of shares, or (iii) combine or reclassify its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect at the time of the record
date for such dividend or distribution or of the effective date of such subdivision, combination or reclassification shall be adjusted so that the Exercise Price shall be proportionately increased (as in the case of (iii), above) or decreased (as in
the case of (i) or (ii), above). Such adjustment shall be made successively whenever any event listed above shall occur. 

  

	 	(2)	In case the Company shall fix a record date for the issuance of rights or warrants to all holders of its Common Stock entitling them to subscribe for or purchase shares
of Common Stock (or securities convertible into Common Stock) at a price (the Subscription Price) (or having a conversion price per share) less than the Exercise Price on such record date, the Exercise Price shall be adjusted so that the same shall
equal such lower price. Such adjustment shall be made successively whenever such rights or warrants are issued and shall become effective immediately after the record date for the determination of shareholders entitled to receive such rights or
warrants; and to the extent that shares of Common Stock are not delivered (or securities convertible into Common Stock are not delivered) 

  
 -4-

	 	
after the expiration of such rights or warrants, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect had the adjustments made upon the issuance of such
rights or warrants been made upon the basis of delivery of only the number of shares of Common Stock (or securities convertible into Common Stock) actually delivered, if any. 

 

	 	(3)	In case the Company shall hereafter distribute to the holders of its Common Stock evidences of its indebtedness or assets (excluding cash dividends or distributions and
dividends or distributions referred to in Subsection (1) above) or subscription rights or warrants (excluding those referred to in Subsection (2) above), the Company shall reserve and the holder of this Warrant shall thereafter, upon
exercise hereof, be entitled to receive with respect to each share of Common Stock purchased hereunder, without any change in, or payment in addition to, the Exercise Price, the amount of any property or other securities which would have been
distributed to such holder had such holder been a holder of one share of Common Stock on the record date of such distribution (or, if no record date was established by the Company, the date such distribution was paid). 

 

	 	(4)	(a) In case the Company shall issue shares of its Common Stock in its IPO at a price to the public that is less than $8.50 per share; as adjusted consistent with
(1) or (2) above (Offering Price), the Exercise Price shall be adjusted immediately after the consummation of the IPO so that it shall equal such Offering Price. (b) In case the Company, prior to its IPO, shall sell all or
substantially all of its assets or be acquired in a merger transaction in either case in which its shareholders receive cash that is less than $10.625 per share; as adjusted consistent with (1) or (2) above (Sale Price), the Exercise Price
shall be adjusted immediately prior to the consummation of the asset sale or merger so that it shall equal 80% of such Sale Price. 

  

	 	(5)	Whenever the Exercise Price payable upon exercise of this Warrant is adjusted pursuant to Subsections (1), (2) or (4) above or (6) below, the number of
shares of Common Stock purchasable upon exercise of this Warrant shall simultaneously be adjusted by multiplying the number of shares of Common Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof
and dividing the product so obtained by the Exercise Price, as adjusted. No other adjustment of the Exercise Price in this section (f) shall cause an adjustment of the number of shares purchasable upon exercise of this Warrant.

  

	 	(6)	The following paragraphs shall only apply (a) prior to the effective date of an IPO of the Company’s shares of common stock and (b) if a transaction
described in this section (f)(6) involves consideration to the Company of more than $5 million. 

  
 -5-

	 	(a)	In case the Company shall issue shares of its Common Stock, excluding shares issued (i) in any of the transactions described in Subsection (1) above,
(ii) in connection with equity grants (including grants of restricted shares of Common Stock) to the Company’s employees under, or upon exercise of options granted to the Company’s employees under, a plan or plans adopted by the
Company’s Board of Directors and approved by its shareholders, if such shares would otherwise be included in this Subsection (6), (iii) upon exercise of any warrant outstanding on the date hereof, (iv) upon conversion of any
securities convertible into or exchangeable for its Common Stock, excluding securities issued in transactions described in Subsections (2) and (3) above, outstanding as of the date hereof, (v) to shareholders of any corporation which
merges into the Company, in proportion to their stock holdings of such corporation immediately prior to such merger, upon the consummation of such merger, or (vi) in a bona fide public offering pursuant to a firm commitment underwriting, but
only if no adjustment is required pursuant to any other specific subsection of this Section (f) (without regard to Subsection (7) below) with respect to the transaction giving rise to such right, for a consideration per share (the Offering
Price) less than the Exercise Price, the Exercise Price shall be adjusted immediately thereafter so that it shall equal such Offering Price. Such adjustment shall be made successively whenever such an issuance is made. 

 

	 	(b)	In case the Company shall issue any securities convertible into or exchangeable for its Common Stock, excluding securities issued in transactions described in
Subsections (2) and (3) above, for a consideration per share of Common Stock (the Conversion Price) initially deliverable upon conversion or exchange of such securities, determined as provided in subsection (6)(c) below, less than the
Exercise Price, the Exercise Price shall be adjusted immediately thereafter so that it shall equal such Conversion Price; and to the extent that shares of Common Stock are not delivered after the expiration of such securities, the Exercise Price
shall be readjusted to the Exercise Price which would then be in effect had the adjustments made upon the issuance of such securities been made upon the basis of delivery of only the number of shares of Common Stock actually delivered, if any. Such
adjustment shall be made successively whenever such an issuance is made. 

  

	 	(c)	For purposes of any computation respecting consideration received pursuant to Subsections (6)(a) and (b) above, the following apply: 

  
 -6-

	 	(A)	in the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash, provided that in no case shall any deduction be made
for any commissions, discounts or other expenses incurred by the Company for any underwriting of the issue or otherwise in connection therewith; 

  

	 	(B)	in the case of the issuance of shares of Common Stock for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be
the fair market value thereof as determined in good faith by the Board of Directors of the Company (irrespective of the accounting treatment thereof), whose determination shall be conclusive; and 

 

	 	(C)	in the case of the issuance of securities convertible into or exchangeable for shares of Common Stock, the aggregate consideration received therefore shall be deemed to
be the consideration received by the Company for the issuance of such securities plus the additional minimum consideration, if any, to be received by the Company upon the conversion or exchange thereof, the consideration in each case to be
determined in the same manner as provided in clauses (A) and (B) of this Subsection (6). 

  

	 	(7)	No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least five cents ($0.05) in such price;
provided, however, that any adjustments which by reason of this Subsection (7) are not required to be made shall be carried forward and taken into account in any subsequent adjustment required to be made hereunder. All calculations under this
Section (f) shall be made to the nearest cent or to the nearest one-hundredth of a share, as the case may be. Anything in this Section (f) to the contrary notwithstanding, the Company shall be entitled, but shall not be required, to make
such changes in the Exercise Price, in addition to those required by this Section (f), as it shall determine, in its sole discretion, to be advisable in order that any dividend or distribution in shares of Common Stock, or any subdivision,
reclassification or combination of Common Stock, hereafter made by the Company shall not result in any Federal income tax liability to the holders of Common Stock or securities convertible into Common Stock (including the Warrant); provided,
however, that no such adjustment shall cause an increase to the Exercise Price then in effect. 

  

	 	(8)	 Whenever the Exercise Price is adjusted, as herein provided, the Company shall promptly but no later than 30 days after any request for such an
adjustment by the Holder, cause a notice setting forth the adjusted 

  
 -7-

	 	
Exercise Price and, if applicable under paragraph (f)(5) above, the adjusted number of shares of Common Stock issuable upon exercise of each Warrant, and, if requested, information describing the
transactions giving rise to such adjustments, to be mailed to the Holder at his last address appearing in the Warrant Register to be maintained by the Company, and shall cause a certified copy thereof to be mailed to its transfer agent, if any.

  

	 	(9)	In the event that at any time, as a result of an adjustment made pursuant to Subsection (1) above, the Holder of this Warrant thereafter shall become entitled to
receive any shares of the Company, other than Common Stock, thereafter the number of such other shares so receivable upon exercise of this Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as
practicable to the provisions with respect to the Common Stock contained in Subsections (1) to (8), inclusive above. 

  

	 	(g)	OFFICER’S CERTIFICATE. Whenever the Exercise Price shall be adjusted as required by the provisions of the foregoing Section, the Company shall forthwith
file in the custody of its Secretary or an Assistant Secretary at its principal office and with its stock transfer agent, if any, an officer’s certificate showing the adjusted Exercise Price determined as herein provided, setting forth in
reasonable detail the facts requiring such adjustment, including a statement of the number of additional shares of Common Stock, if any, and such other facts as shall be necessary to show the reason for and the manner of computing such adjustment.
Each such officer’s certificate shall be made available at all reasonable times for inspection by the Holder or any holder of a Warrant executed and delivered pursuant to Section (a) hereof and the Company shall, forthwith after each such
adjustment, mail a copy by certified mail of such certificate to the Holder or any such holder. 

  

	 	(h)	 NOTICES TO WARRANT HOLDERS. So long as this Warrant shall be outstanding, (i) if the Company shall pay any dividend or make any
distribution upon the Common Stock or (ii) if the Company shall offer to the holders of Common Stock for subscription or purchase by them any share of any class or any other rights or (iii) if any capital reorganization of the Company,
reclassification of the capital stock of the Company, consolidation or merger of the Company with or into another corporation, sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation, or
voluntary or involuntary dissolution, liquidation or winding up of the Company shall be effected, then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least fifteen days prior to the date specified in
(x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution or rights, or (y) such
reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation 

  
 -8-

	 	
or winding up is to take place and the date, if any is to be fixed, as of which the holders of Common Stock or other securities shall receive cash or other property deliverable upon such
reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation or winding up. 

  

	 	(i)	RECLASSIFICATION, REORGANIZATION OR MERGER. In case of any reclassification, capital reorganization or other change of outstanding shares of Common Stock of the
Company, or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary in which merger the Company is the continuing corporation and which does not result in any reclassification,
capital reorganization or other change of outstanding shares of Common Stock of the class issuable upon exercise of this Warrant) or in case of any sale, lease or conveyance to another corporation of the property of the Company as an entirety, the
Company shall, as a condition precedent to such transaction, cause effective provisions to be made so that the Holder shall have the right thereafter by exercising this Warrant at any time prior to the expiration of the Warrant, to purchase the kind
and amount of shares of stock and other securities and property receivable upon such reclassification, capital reorganization and other change, consolidation, merger, sale or conveyance by a holder of the number of shares of Common Stock which might
have been purchased upon exercise of this Warrant immediately prior to such reclassification, change, consolidation, merger, sale or conveyance. Any such provision shall include provision for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications, capital reorganizations and changes of shares of Common Stock and to successive
consolidations, mergers, sales or conveyances. In the event that in connection with any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares of Common Stock shall be issued in exchange,
conversion, substitution or payment, in whole or in part, for a security of the Company other than Common Stock, any such issue shall be treated as an issue of Common Stock covered by the provisions of Subsection (1) of Section (f) hereof.

  

	 	(j)	REGISTRATION UNDER THE SECURITIES ACT OF 1933. The Company has entered into a certain Registration Rights Agreement with the Holder, which Agreement shall
continue in effect regardless of the exercise and surrender of this Warrant, but only for one year after such exercises. 

  

	 	(k)	 RESTRICTIVE LEGEND. Each Warrant Share, when issued, shall include a legend in substantially the following form: THESE SHARES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE ACT) NOR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNTIL A (1) REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAW
HAS BECOME EFFECTIVE WITH RESPECT 

  
 -9-

	 	
THERETO, OR (2) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW IS NOT REQUIRED IN CONNECTION
WITH THE PROPOSED TRANSFER. 

  

	(l)	The Company will not, by amendment of its charter or through reorganization, consolidation, merger, dissolution, sale of assets or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the Holder of this Warrant against impairment. 

  

	(m)	Acceptance of this Warrant shall be deemed to cancel a warrant previously issued to the Holder dated August 27, 2012 as provided in the restated credit agreement
pursuant to which this Warrant is being granted. 

 Dated: October 17, 2012 

 

							
		 		 	CANCER GENETICS, INC.
				
	Attest:	 		 		 	
				
	 	 		 	By:	 	 
	Name:	 		 		 	Name: Panna Sharma
	Title:	 		 		 	Title: President and CEO

  
 -10-

 PURCHASE FORM 
 Dated                     20     

The undersigned hereby irrevocably elects to exercise the within Warrant to the extent of
purchasing                 shares of Common Stock and hereby makes payment of
                 in payment of the actual exercise price thereof. 
  

 
 INSTRUCTIONS
FOR REGISTRATION OF STOCK 
 Name
                                         
                                         
                                         
                      

                         
                   (Please typewrite or print in block letters) 
 Address                                
                                         
                                         
                           
 Signature
                                         
                                         
                           
  

 
 ASSIGNMENT
FORM 
 FOR VALUE
RECEIVED,                                       
                                      hereby sells, assigns
and transfers unto 

Name                        
                                         
                                         
                                   

                         
                   (Please typewrite or print in block letters) 
 Address                                
                                         
                                         
                           
 the right to purchase Common Stock represented by this Warrant to the extent of                 shares as to which
such right is exercisable and does hereby irrevocably constitute and appoint
                                         
    Attorney, to transfer the same on the books of the Company with full power of substitution in the premises. 
 Date
                    , 20     
 SignatureRestated Registration Rights Agreement

 Exhibit 10.54 
 REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION RIGHTS AGREEMENT
(this “Agreement”), dated as of this October 17, 2012, is made by and between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and Mark Oman (“Oman”), and John Pappajohn (“Pappajohn”)
(collectively the “Investor”). The Company and the Investor are sometimes referred to herein, individually, as a “Party,” and, collectively, as the “Parties.” 

WITNESSETH: 

WHEREAS, the Company and the Investor have entered into a restated credit agreement, of even date herewith (the “Credit
Agreement”), whereby the Investor has agreed to extend a $3,000,000 loan to the Company, as evidenced by two convertible promissory notes (collectively, the “Note”) which Note is convertible under the terms of the Credit Agreement
into an aggregate of 352,941 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), subject to adjustment as provided in the Credit Agreement; and 

WHEREAS, in consideration of the Investor entering into the Credit Agreement with the Company, the Company issued warrants (the
“Warrants”) to purchase in the aggregate collectively a minimum of 572,549 and a maximum of 643,139 shares of the Common Stock, subject to adjustment as provided in the Warrant Agreement, to the Investor, and the Company has agreed to
provide the registration rights and other rights set forth in this Agreement with respect to the Registrable Shares (as defined below). 
 NOW, THEREFORE, in consideration of the premises and covenants hereafter contained, the Parties, intending to be legally bound, hereby agree as follows: 

 

	 	1.	Registration Rights.  

  

	 	1.1	Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

(a) “Business Day” shall mean any day that is not a Saturday, a Sunday or a day on which banks are required or permitted to be
closed in the State of New York. 
 (b) “Commission” shall mean the Securities and Exchange Commission, or any other
federal agency at the time administering the Securities Act. 
 (c) “Company” shall mean Cancer Genetics, Inc., or if
Investor holds any Conversion Shares issued by an entity other than Cancer Genetics, Inc., then “Company” shall also include the issuer of such Conversion Shares. 
 (d) “Conversion Shares” shall mean shares of Common Stock issued or issuable upon conversion of the Note or exercise of the Warrant, and including any common stock issued, or issuable, with
respect to securities issued in exchange for shares of Common Stock in connection with a merger or other corporate reorganization involving Cancer Genetics, Inc. 

 (e) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or
any similar federal statute, and the rules and regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 
 (f) “Holder” shall mean each holder of the Registrable Shares, or any portion of the Registrable Shares, including any person to whom the rights granted under this Agreement are transferred
pursuant to Section 1.2 hereof. 
 (g) “Initial Public Offering” shall mean the initial underwritten sale of
equity securities by the Company pursuant to an effective Registration Statement under the Securities Act. 
 (h)
“Registrable Shares” shall mean the Conversion Shares, but shall exclude Conversion Shares (i) which have been registered under the Securities Act pursuant to an effective Registration Statement filed thereunder and disposed of in
accordance with the registration statement covering them, or (ii) which have been publicly sold pursuant to Rule 144 or Rule 701 under the Securities Act. 
 (i) “Registration Statement” shall mean a registration statement filed by the Company with the Commission for a public offering and sale of securities of the Company (other than a registration
statement on Form S-8 or Form S-4, or their successors, or any other form for a limited purpose, or any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation). 

(j) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and
regulations of the Commission issued under the Securities Act, as they each may, from time to time, be in effect. 
 1.2
Assignment of Registration Rights. The rights to cause the Company to register Registrable Shares pursuant to this Section 1 may be assigned (but only with all related obligations of the Investor under this Agreement) by the Investor and
each subsequent Holder; provided, however, that the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the securities with respect to which such registration rights
are being assigned. 
 1.3 Incidental Registration. 

(a) Opportunity to Participate. Other than with respect to a Registration Statement to be filed in connection with the
Company’s Initial Public Offering, at any time after a date more than 181 days after the consummation of an Initial Public Offering, and so long as not otherwise inconsistent with any Lock Up agreement given to the Company’s underwriters
in the Initial Public Offering, whenever the Company proposes to file a Registration Statement (other than by a registration on Form S-4 or Form S-8, any successor forms, or any form not available for registering shares for sale to the public
pursuant to a public offering or pursuant to registrations in which the only stock being registered is Common Stock issuable upon conversion of debt securities which are also being registered) at any time and from time to

  
 - 2 -

 
time, it will, prior to such filing, give written notice to all Holders of its intention to do so and, upon the written request of a Holder or Holders given within thirty (30) days after the
Company provides such notice, the Company shall use reasonable commercial efforts to cause all Registrable Shares owned by such Holders, which the Company has been requested by such Holder or Holders to register, to be registered under the
Securities Act; provided that the Company shall have the right to postpone or withdraw any registration effected pursuant to this Section 1.3 without obligation to any Holder. 

(b) Demand Registration. The Holders of a majority of the Registrable Shares shall be entitled to require that the Company
register for their resale under the Securities Act the Registrable Shares. Such demand shall be exercisable by delivery of written notice by the Holders of a majority of Registrable Shares to the Company. Such Holders may deliver such written notice
at any time; provided, however, that the obligation of the Company to file a Registration Statement shall not accrue until a date which is (i) 90 days after the completion of the Company’s merger with a public shell company pursuant to
which the public shell company merges with the Company or acquires (the “Acquisition”) all of the outstanding securities of the Company in exchange for issuance of securities of the public shell company or (ii) 181 days after the
consummation of the Company’s Initial Public Offering (or such later date as may be necessary to comply with the terms of the underwriting agreement to be entered into by the Company and the underwriters in connection with the Company’s
Initial Public Offering and any lock up agreements any Holder has executed in favor of such underwriters). Upon receipt of any such demand notice, the Company shall use reasonable efforts to file the Registration Statement as promptly as possible,
but in no event more than 60 days after receipt of such demand (subject to the completion of the Acquisition as stated above), and shall use its reasonable efforts to have such Registration Statement declared effective by the SEC as promptly as
possible. 
 (c) Terms; Exclusions. In connection with any offering under this Section 1.3 involving an
underwriting, the Company shall not be required to include any Registrable Shares in such underwriting unless the Holders thereof accept the terms of the underwriting as agreed upon between the Company and the underwriter selected by the Company,
and then only in such quantity as will not, in the opinion of the underwriters, adversely affect the offering by the Company. If in the opinion of the managing underwriter the registration of all, or part of, the Registrable Shares which the Holders
have requested to be included would adversely affect such public offering, then the Company shall be required to include in the underwriting only that number of Registrable Shares, if any, which the managing underwriter believes may be sold without
causing such adverse effect. If the number of Registrable Shares to be included in the underwriting in accordance with the foregoing is less than the total number of shares which the Holders of Registrable Shares have requested to be included, then
the Company may include all securities proposed to be registered by the Company to be sold for its own account and the securities (or any portion thereof) of any other stockholder electing to participate in the offering for which registration rights
with respect to such securities were granted by the Company before the date of this Agreement, and the Holders of Registrable Shares who have requested registration shall participate in the underwriting pro rata based upon their total ownership of
Registrable Shares requested to be registered; provided, however, that the number of Registrable Shares included in such underwriting shall not be reduced unless all other securities of any other stockholder electing to participate in the offering
for which 

  
 - 3 -

 
registration rights were granted with respect to such securities after the date of this Agreement are first excluded from the underwriting and offering. If any Holder would thus be entitled to
include more shares than such Holder requested to be registered, the excess shall be allocated among other requesting Holders pro rata based upon their total ownership of Registrable Shares. 

(d) Underwriting Agreement. All Holders of Registrable Shares proposing to distribute their securities in an offering under this
Section 1.3 involving an underwriting shall (together with the Company and other shareholders, if any, of securities distributing their shares through such underwriting) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for the underwriting. 
 1.4 Registration Procedures. If and whenever the Company is
required by the provisions of this Agreement to use commercially reasonable efforts to effect the registration of any of the Registrable Shares under the Securities Act, the Company shall: 

(a) prepare and file with the Commission a Registration Statement with respect to such Registrable Shares and use commercially reasonable
efforts to cause that Registration Statement to become and remain effective for the period of the distribution contemplated thereby (determined as hereinafter provided); 
 (b) prepare and file with the Commission any amendments and supplements to the Registration Statement and the prospectus in connection therewith as may be necessary to keep the Registration Statement
effective until the earliest of (i) the period of time required by the Commission, (ii) one hundred eighty (180) days from the effective date, or (iii) the sale of all Registrable Shares covered thereby; provided, that the
Company may discontinue any registration of its securities that are not Registrable Shares (and, under the circumstances specified in Section 1.3(a), its securities that are Registrable Shares) at any time prior to the effective date of such
Registration Statement; 
 (c) furnish to each selling Holder such reasonable number of copies of the prospectus, including each
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as the selling Holder may reasonably request in order to facilitate the public sale or other disposition of the Registrable Shares owned by
the selling Holder; 
 (d) use commercially reasonable efforts to register or qualify the Registrable Shares covered by the
Registration Statement under the securities or blue sky laws of such states as the selling Holders shall reasonably request, and do any and all other acts that may be necessary or desirable to enable the selling Holders to consummate the public sale
or other disposition in such states of the Registrable Shares owned by the selling Holder; provided, however, that the Company shall not be required in connection with this Section 1.4(d) to qualify as a foreign corporation or execute a general
consent to service of process in any jurisdiction; 
 (e) notify each Holder of Registrable Shares covered by the registration
statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event of which the Company has knowledge as 

  
 - 4 -

 
a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. Each Holder of Registrable Shares agrees upon receipt of such notice forthwith to cease making offers and sales of Registrable
Shares pursuant to such Registration Statement or deliveries of the prospectus contained therein for any purpose until the Company has prepared and furnished such amendment or supplement to the prospectus as may be necessary so that, as thereafter
delivered to purchasers of such Registrable Shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in
the light of the circumstances then existing; 
 (f) if the offering is underwritten and at the request of any Holders of
Registrable Shares, use commercially reasonable efforts to furnish on the date that Registrable Shares are delivered to the underwriters for sale pursuant to such registration: 

(i) an opinion dated such date of counsel representing the Company for the purposes of such registration, addressed to the underwriters
and to such Holder, stating that such Registration Statement has become effective under the Securities Act and that (A) to the best knowledge of such counsel, no stop order suspending the effectiveness thereof has been issued and no proceedings
for that purpose have been instituted or are pending or contemplated under the Securities Act, and (B) to such other effect as reasonably may be requested by counsel for the underwriters or by such Holder or its counsel; and 

(ii) a letter dated such date from the independent certified public accountants retained by the Company, addressed to the underwriters
and to such Holder, stating that they are independent certified public accountants within the meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the Registration Statement
or the prospectus, or any amendment or supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including
information as to the period ending no more than five Business Days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; 

(g) make available for inspection upon reasonable notice during the Company’s regular business hours by each Holder of Registrable
Shares, any underwriter participating in any distribution pursuant to such Registration Statement, and any attorney, accountant or other agent retained by such Holder or underwriter, all financial and other records, pertinent corporate documents and
properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such Holder, underwriter, attorney, accountant or agent in connection with such Registration Statement;
and 
 (h) provide a CUSIP number for all Registrable Shares covered by such Registration Statement not later than the effective
date of such Registration Statement and, if applicable, provide the Company’s transfer agent with printed certificates for such Registrable Shares which are in a form eligible for deposit with the Depositary Trust Company. 

  
 - 5 -

 In connection with each registration hereunder, each Holder of Registrable Shares shall
(a) provide such information and execute such documents as may reasonably be required in connection with such registration, (b) agree to sell Registrable Shares on the basis provided in any underwriting arrangements, and (c) complete
and execute all questionnaires, powers of attorney, indemnities, underwriting agreements, and other documents required under the terms of such underwriting arrangements, which arrangements shall not be inconsistent herewith. 

In connection with each registration pursuant to Section 1.4 covering an underwritten public offering, the Company and each Holder
agree to enter into a written agreement with the managing underwriter selected in the manner herein provided in such form and containing such provisions as are customary in the securities business of such an arrangement between such underwriter and
companies of the Company’s size and investment stature. 
 1.5 Allocation of Expenses. The Company will pay all
Registration Expenses (as hereinafter defined) incurred with any registration, filing or qualification of Registrable Shares under this Agreement. For purposes of this Agreement, the term “Registration Expenses” shall mean all expenses
incurred by the Company in complying with this Section 1, including without limitation, all registration and filing fees, exchange listing fees, printing expenses, the fees and disbursements of counsel for the Company and the reasonable fees
and disbursements of one counsel selected by the selling Holders (not to exceed an aggregate amount of $15,000 per registration), the fees and disbursements of the Company’s accountants, state blue sky fees and expenses, and the expense of any
special audits incident to or required by any such registration, but excluding underwriting discounts, transfer taxes, selling commissions and the fees and expenses of the selling Holders’ own counsel (other than the one counsel selected to
represent all of the selling Holders). 
 1.6 Indemnification. 

(a) In the event of registration of any of the Registrable Shares under the Securities Act pursuant to this Agreement, the Company will
defend, indemnify and hold harmless the seller of such Registrable Shares, each of its directors, officers or partners, each underwriter (if any) within the meaning of the Exchange Act (an “Underwriter”) of such Registrable Shares and each
other person, if any, who controls such seller or Underwriter within the meaning of the Securities Act or the Exchange Act (a “controlling person”) against any losses, claims, damages or liabilities, joint or several, to which such seller
or Underwriter or controlling person may become subject under the Securities Act, the Exchange Act, blue sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon
(i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus
contained in such Registration Statement, or any amendment or supplement to such Registration Statement, (ii) the omission or alleged omission to state a material fact required to be stated therein or

  
 - 6 -

 
necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or (iii) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act, any federal securities or state blue sky law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any federal securities or blue sky law in connection with the offering covered by such
Registration Statement; and the Company will reimburse such seller or Underwriter and each such controlling person for any legal or any other expenses reasonably incurred by such seller or Underwriter or controlling person in connection with
investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any
untrue statement or omission made in such Registration Statement, preliminary prospectus or prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by or on behalf of
such seller, Underwriter or controlling person specifically for use in the preparation thereof or if such misstatement or omission was corrected in any amendment or supplement provided to a selling Holder pursuant to Section 1.4(b) and
(c) and the selling Holder failed to deliver such amendment or supplement. 
 (b) In the event of any registration of any
of the Registrable Shares under the Securities Act pursuant to this Agreement, each seller of Registrable Shares, severally and not jointly, will indemnify and hold harmless the Company, each of its directors and officers, each Underwriter (if any)
and each controlling person, if any, of the Company or Underwriter against any losses, claims, damages or liabilities, joint or several, to which the Company, such directors and officers, any Underwriter or controlling persons may become subject
under the Securities Act, Exchange Act, blue sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a
material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus contained in such Registration Statement, or any amendment or
supplement to such Registration Statement, or (ii) any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were
made, not misleading, if the statement or omission or was made or occurred in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of such seller of Registrable Shares, specifically for use in
connection with the preparation of such Registration Statement, prospectus, amendment or supplement or if such misstatement or omission was corrected in any amendment or supplement provided to such seller of Registrable Shares pursuant to
Section 1.4(b) and (c) and such seller of Registrable Shares failed to deliver such amendment or supplement, or (iii) any violation or alleged violation by such seller of Registrable Shares of the Securities Act, the Exchange Act, any
federal securities or blue sky law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any federal securities or blue sky law in connection with the offering covered by such Registration Statement; and each seller of
such Registrable Shares will reimburse the Company and each such director, officer or Underwriter and each such controlling person for any legal or any other expenses reasonably incurred by the Company, such director, officer or Underwriter or such
controlling person in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the obligations of each such seller of Registrable Shares hereunder shall be limited to an amount
equal to the net proceeds to each such seller of Registrable Shares sold as contemplated herein. 

  
 - 7 -

 (c) Each Party entitled to indemnification under this Section 1.6 (the
“Indemnified Party”) shall give notice to the Party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and
shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, however, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be
approved by the Indemnified Party (whose approval shall not be unreasonably withheld, conditioned or denied); and, provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying
Party of its obligations under this Section 1.6 unless the failure to give such notice timely actually effects in a material manner the Indemnifying Party. The Indemnified Party may participate in such defense at such party’s expense;
provided, however, that the Indemnifying Party shall pay such expense if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between the
Indemnified Party and any other party represented by such counsel in such proceeding. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party, consent to entry of any judgment or
enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation, and no further obligation to
indemnify an Indemnified Party shall exist in connection with either of the following situations without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld: (i) judgment entered with the
consent of the Indemnified Person; or (ii) settlement of such claim or litigation. The right to indemnification in this Section 1.6 shall survive indefinitely. 
 1.7 Information by Holder. 
 (a) Each Holder of Registrable Shares included
in any registration shall furnish to the Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be required in connection with any registration,
qualification or compliance referred to in this Section 1. 
 (b) Each Holder of Registrable Shares shall use reasonable
efforts to report to the Company sales made pursuant to any registration of such Registrable Shares. 
 1.8 “Market
Stand-Off” Agreement. (a) Each Holder, if requested by the Company and an underwriter of Common Stock or other securities of the Company, shall agree not to sell or otherwise transfer or dispose of any Registrable Shares or other
securities (other than shares of Common Stock being registered in such offering) of the Company held by such Holder for a specified period of time (not to exceed one hundred eighty one (181) days) following the effective date of a Registration
Statement; provided, however, that such restriction shall apply only to the Registration Statement relating to the Company’s Initial Public Offering, and shall not extend to any securities included in such Registration Statement; and provided

  
 - 8 -

 
further that all officers and directors of the Company shall agree to be bound by such restriction and the Company shall use all reasonable efforts to obtain a similar covenant from each holder
of at least one percent (1%) of the outstanding capital stock of the Company. Such agreement shall be in writing in a form satisfactory to the Company and such underwriter. The Company may impose stop transfer instructions with respect to the
Registrable Shares or other securities subject to the foregoing restriction until the end of the market stand-off period. 
 (b)
In addition, each Holder shall execute a Lock-Up Account in the form annexed to the Credit Agreement simultaneously with execution of this Agreement. In the event of any conflict, the Lock Up Agreement shall prevail. 

2. Miscellaneous.  
 2.1 Termination. The registration rights granted under Section 1 herein will terminate on the earlier of: (i) with respect to all Holders, the expiration or termination date of the
Warrants, or (ii) with respect to all Holders, such time as Rule 144 promulgated under the Securities Act (“Rule 144”) or another similar exemption under the Securities Act is available (assuming, with respect to the Warrant Shares,
the cashless exercise provisions of the Warrant are utilized) for the sale of Registrable Shares during a three-month period without registration and without other restrictions other than those set forth in paragraphs (f) and (g) of Rule
144. 
 2.2 Rule 144. Upon the written request of any Holder, the Company will deliver to such Holder a written statement
as to whether it has complied with the filing requirements under Rule 144(c)(1) or any successor thereto. 
 2.3
Recapitalizations, Exchanges, etc. Except as otherwise provided in this Agreement, the provisions of this Agreement shall apply to any and all shares of capital stock or other securities of the Company or any successor or assignor of the
Company (whether by merger, consolidation, sale of assets, transfer of equity interests or otherwise) which may be issued in respect of, in exchange for, or in substitution of, any Registrable Shares by reason of any reorganization,
recapitalization, reclassification, merger, consolidation, partial or complete liquidation, sale of assets, spin-off, stock dividend, split, distribution to stockholders or combination of the shares of Common Stock or any other change in the
Company’s capital structure, in order to preserve fairly and equitably as far as practicable, the original rights and obligations of the Parties hereto under this Agreement. The Company shall use its best efforts to cause any successor or
assignor (whether by sale, merger or otherwise) to enter into a new registration rights agreement with the Holders on terms substantially the same as this Agreement as a condition of any such transaction. 

2.4 Notices. All notices, requests, consents and other communications hereunder shall be in writing and shall be personally
delivered or delivered by overnight courier or mailed by first-class registered or certified mail, postage prepaid, return receipt requested, or by facsimile transmission. Every notice hereunder shall be deemed to have been duly given or served on
the date on which personally delivered, with receipt acknowledged, upon transmission by facsimile and confirmed facsimile receipt. 

  
 - 9 -

	 	(a)	If to the Investor at: 

  

	 	    	Attn: 

  

	 	    	with a copy to: 

  

	 	    	Attn: 

  

	 	(c)	If to the Company at: 

  

	 	    	Cancer Genetics, Inc. 

	 	    	 201 Route 17 North,
2nd Floor 

	 	    	Rutherford, New Jersey 07070 

	 	    	Attention: President 

  

	 	    	with a copy to: 

  

	 	    	Lowenstein Sandler PC 

	 	    	65 Livingston Avenue 

	 	    	Roseland, New Jersey 07068 

	 	    	Attn: Alan Wovsaniker, Esq. 

 2.5
Amendments and Waiver. Unless otherwise specifically stated herein, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either
retroactively or prospectively), with the written consent of the Company and the Holders of a majority of Registrable Shares, which amendment or waiver, as the case may be, shall be binding on the Company and all of the Holders, if, and to the
extent that, such amendment or waiver treats all Holders in the same manner. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such term, condition or provision. 
 2.6 Entire Agreement. This Agreement embodies the entire
agreement and understanding between the Parties and supersedes all prior agreements and understandings relating to the subject matter hereof. 
 2.7 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement. 

2.8 Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware without
regard to conflicts of law principles. 

  
 - 10 -

 2.9 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall be binding upon, and inure to the benefit of, the respective representatives, successors and assigns of the Parties. 
 2.10 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

[SIGNATURE PAGE TO FOLLOW] 

  
 - 11 -

 IN WITNESS WHEREOF, each Party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

			
	 COMPANY

CANCER GENETICS, INC.

		
	By:	 	 
		 	 Name:

Title:

  

	
	 INVESTOR
  

 

	 John Pappajohn            

 
  

	Mark Oman

  
 - 12 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]